KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Payables: 2011-2025

Historic Payables for Travere Therapeutics (TVTX) over the last 14 years, with Sep 2025 value amounting to $18.2 million.

  • Travere Therapeutics' Payables fell 21.43% to $18.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.3 million, marking a year-over-year decrease of 29.01%. This contributed to the annual value of $23.5 million for FY2024, which is 43.53% down from last year.
  • Travere Therapeutics' Payables amounted to $18.2 million in Q3 2025, which was down 4.75% from $19.1 million recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Payables ranged from a high of $41.7 million in Q4 2023 and a low of $5.8 million during Q3 2021.
  • Its 3-year average for Payables is $22.3 million, with a median of $19.9 million in 2023.
  • In the last 5 years, Travere Therapeutics' Payables soared by 141.04% in 2023 and then crashed by 43.53% in 2024.
  • Over the past 5 years, Travere Therapeutics' Payables (Quarterly) stood at $15.1 million in 2021, then climbed by 14.17% to $17.3 million in 2022, then surged by 141.04% to $41.7 million in 2023, then slumped by 43.53% to $23.5 million in 2024, then declined by 21.43% to $18.2 million in 2025.
  • Its Payables stands at $18.2 million for Q3 2025, versus $19.1 million for Q2 2025 and $15.4 million for Q1 2025.